Alligator Bioscience
- Company typePublic
- Founded1997
- HeadquartersLund, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Alligator Bioscience firmographics
Firmographics- Name
- Alligator Bioscience
- Legal name
- Alligator Bioscience AB
- Website
- https://alligatorbioscience.se
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Alligator Bioscience industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Alligator Bioscience is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Alligator Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Distribution channels1 record
Marketing channels3 records
Alligator Bioscience product offering
Product offeringCore offering
Alligator Bioscience is a clinical-stage biotechnology company developing antibody-based immunotherapies for cancer treatment. Its portfolio centers on tumor-directed mono- and bispecific antibodies targeting the CD40 receptor and other immune pathways, including the lead candidate mitazalimab (a CD40 agonist for pancreatic cancer), the bispecific ATOR-4066 (CD40xCEACAM5), ALG.APV-527 (4-1BBx5T4), and ATOR-1017 (4-1BB agonist). The company also licenses the anti-HER2 antibody HLX22 via Shanghai Henlius, and offers proprietary bispecific platforms Neo-X-Prime and RUBY for partnership-based development.
Product overview
Alligator Bioscience is a clinical-stage Swedish biotechnology company developing tumor-directed immuno-oncology antibody drugs. The company's portfolio consists of agonistic monoclonal and bispecific antibodies targeting the CD40 receptor and other immune pathways for cancer treatment. The core pipeline includes: Mitazalimab (lead CD40 agonist antibody in Phase 3 preparation for pancreatic cancer), ATOR-4066 (CD40×CEACAM5 bispecific using Neo-X-Prime™ platform), ALG.APV-527 (4-1BB×5T4 bispecific co-developed with Aptevo), and ATOR-1017 (4-1BB agonist). Additionally, HLX22 (anti-HER2 antibody) is licensed to Henlius with Alligator receiving revenue shares. The company also offers its proprietary RUBY™ bispecific antibody platform for partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- Mitazalimab Tumor-directed CD40 agonist monoclonal antibody in clinical development (Phase 3 preparation) for metastatic pancreatic cancer in combination with mFOLFIRINOX chemotherapy. Targets oncology patients with limited treatment options.
- ATOR-4066 (Neo-X-Prime) Bispecific antibody built on the proprietary Neo-X-Prime format, targeting CD40 and CEACAM5 antigens, intended for next-generation immunotherapies in multiple oncology indications.
- ALG.APV-527 First-in-class bispecific antibody co-developed with Aptevo Therapeutics, targeting 4-1BB and 5T4 tumor antigen for immune activation in solid tumors; Phase 1 reported 60% of evaluable patients with stable disease.
- ATOR-1017 (evunzekibart) 4-1BB (CD137) agonist monoclonal antibody designed for immune activation in patients with advanced solid malignancies.
- HLX22 (AC101) Anti-HER2 monoclonal antibody originally developed by AbClon, sublicensed to Shanghai Henlius Biotech; in Phase 2/3 for HER2-positive breast cancer and Phase 3 for gastric cancer. Alligator is entitled to 35% of AbClon's revenue from the Henlius sublicense.
- RUBY Bispecific Antibody Platform Proprietary tetravalent bispecific antibody format enabling stable assembly of bispecific antibodies with dual antigen binding capability, offered through evaluation/option agreements to partners for next-generation immunotherapy development.
Quantifiable outcome
- 87% clinical benefit rate and 81% remission rate in acute myeloid leukemia patients
- +1 more outcomes
Companies that use Alligator Bioscience
Customer profileSegments1 record
Ideal customer profiles2 records
Alligator Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alligator Bioscience partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor and core.
- RUBY Antibody Format PartnerminorEvaluation and option agreement covering RUBY antibody format signed in September 2025, supporting company's strategy to build long-term value through partnerships.
- AmpheraminorCollaboration on REACtiVe-2 Phase 1 study combining mitazalimab with Amphera's MesoPher cell therapy in pancreatic cancer. Both companies announced last patient treated in the study.
- Aptevo TherapeuticscoreCo-development partnership for ALG.APV-527, a bispecific antibody targeting 5T4 tumor antigen. Companies presented positive Phase 1 data showing 60% of evaluable patients achieved stable disease. Jointly advancing clinical development for solid tumor cancers.
- University of PennsylvaniaminorSponsored research agreement led by Dr. Gregory Beatty for preclinical and clinical research on mitazalimab and related immunotherapies.
- Erasmus University RotterdamminorInvestigator-initiated Phase 1 clinical trial of mitazalimab conducted at Erasmus Medical Center.
- Shanghai Henlius BiotechcorePartnership for development of HLX22 (also known as AC101), an anti-HER2 monoclonal antibody. Henlius is conducting Phase 2/3 trials in breast cancer and Phase 3 in gastric cancer. Alligator is entitled to 35% of AbClon's revenue from sublicense agreements with Henlius.
- Scandion OncologyminorCollaboration on preclinical data supporting efficacy of mitazalimab in combination therapy with Scandion's lead compound.
- Orion CorporationcoreImmuno-oncology Research Collaboration and License Agreement signed in August 2021 for the development of novel immuno-oncology drugs. Orion exercised development options under the agreement, and Alligator received milestone payments. Collaboration includes multiple programs with Orion taking responsibility for future development and commercialization.
- AbCloncoreOriginal developer of HLX22/AC101 antibody. Alligator holds rights to the molecule and sublicenses to partners like Henlius. Receives 35% of AbClon's revenue from sublicense agreements.
- BioArcticminorResearch agreement in the neurodegenerative field, exploring potential applications of antibody technology beyond oncology.
- MacroGenicsminorResearch collaboration to develop a novel immunotherapy combining双方的抗体技术平台。
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Alligator Bioscience competitors and assessment
Company assessmentDirect peers
- Aptevo Therapeutics: Direct co-development partner on ALG.APV-527 (4-1BBx5T4 bispecific) and a clinical-stage immuno-oncology company building bispecific antibody candidates with a comparable technology profile to Alligator's pipeline.
- MacroGenics: Clinical-stage oncology company with proprietary bispecific antibody platforms (DART, TRIDENT) and a pipeline of immuno-oncology antibodies, including 4-1BB and HER2-targeted assets directly comparable to Alligator's bispecific strategy. Alligator has a research collaboration with MacroGenics.
- Genmab: Pioneer in bispecific antibody technology (DuoBody, HexaBody) with a broad clinical-stage oncology pipeline; competes in the same bispecific antibody modality space as Alligator's RUBY and Neo-X-Prime platforms.
Emerging players
- Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that activate myeloid and antigen-presenting cells via agonist antibodies — closely analogous mechanism to Alligator's CD40 agonist strategy.
- Werewolf Therapeutics: Clinical-stage company developing INDUKINE™ conditionally activated immune agonists for oncology, targeting the same space of tumor-directed immune activation as Alligator's CD40 agonist pipeline.
- CytomX Therapeutics: Clinical-stage oncology company with a Probody® masked antibody platform for tumor-selective activation, offering an alternative approach to tumor-directed antibody therapeutics comparable to Alligator's tumor-directed CD40 design.
- Compugen: Computational immuno-oncology company with clinical-stage antibody programs targeting novel immune checkpoints, representing a comparable clinical-stage IO platform player with similar size and stage.
- Mereo BioPharma: Clinical-stage biopharmaceutical company with a comparable size and oncology/rare disease pipeline profile, sharing similar late-clinical-stage small-cap dynamics and partnering-driven business model.
Broad incumbents
- Roche: Global oncology leader with multiple CD20/CD40 agonist programs (e.g., mitazalimab-like CD40 agonist efforts) and a broad bispecific antibody franchise, serving as the dominant large-pharma competitor in Alligator's target space.
- AstraZeneca: Major oncology incumbent with extensive immuno-oncology, bispecific antibody (e.g., bispecific T-cell engagers) and CD40 agonist programs, representing a large-pharma benchmark for Alligator's immuno-oncology strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Alligator Bioscience social profiles
Digital presenceAlligator Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alligator Bioscience leadership team
Management profileNumber of profiles
Profiles6 records
Alligator Bioscience funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alligator Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alligator Bioscience
What does Alligator Bioscience do?
Alligator Bioscience is a clinical-stage biotechnology company developing antibody-based immunotherapies for cancer treatment. Its portfolio centers on tumor-directed mono- and bispecific antibodies targeting the CD40 receptor and other immune pathways, including the lead candidate mitazalimab (a CD40 agonist for pancreatic cancer), the bispecific ATOR-4066 (CD40xCEACAM5), ALG.APV-527 (4-1BBx5T4), and ATOR-1017 (4-1BB agonist). The company also licenses the anti-HER2 antibody HLX22 via Shanghai Henlius, and offers proprietary bispecific platforms Neo-X-Prime and RUBY for partnership-based development.
Is Alligator Bioscience a public or private company?
Alligator Bioscience is a public company. It is classified as public and is currently operating.
When was Alligator Bioscience founded?
Alligator Bioscience was founded in 1997. It employs 11 to 50 people.
Where is Alligator Bioscience based?
Alligator Bioscience is headquartered in Lund, Sweden, in the Europe region.
Who are Alligator Bioscience's main competitors?
Direct peers on record are Aptevo Therapeutics, MacroGenics and Genmab. Emerging players are Bolt Biotherapeutics, Werewolf Therapeutics, CytomX Therapeutics, Compugen and Mereo BioPharma. Broad incumbents are Roche and AstraZeneca.
Does Alligator Bioscience have an API?
No public API is recorded for Alligator Bioscience.
What industry is Alligator Bioscience in?
Alligator Bioscience's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.